Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACC Meeting ENHANCE Panel Calls For Return To Statins

This article was originally published in The Pink Sheet Daily

Executive Summary

The failed atherosclerosis study provides “no new evidence to support the use of this drug,” a cardiology panel says.
Advertisement

Related Content

ACCORD, ADVANCE Kick Off ADA’s Day One
Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales
UnitedHealth Maintains Status Quo On Vytorin For Now, But CIGNA Revises Step Therapy Policy
Schering-Plough’s Vytorin “Permanently Broken,” Analyst Says
Schering-Plough Cutback Target: $1.5 Billion
Grassley Investigates Merck/Schering’s Spending On Vytorin Promotion
Stars Align For AstraZeneca In JUPITER Trial
Abbott’s Phase III Fenofibrate Works With Statins
Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction
Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction

Topics

Advertisement
UsernamePublicRestriction

Register

PS067503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel